Completed
AL Amyloidosis Pathogenesis is Entirely Related to Immunoglobulin Free Light Chain (FLC) Deposition
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Updates on AL Amyloidosis Treatment - What is New in 2023
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Amyloidoses-Basic Concepts
- 3 AL Amyloidosis is a Plasma Cell Disorder
- 4 AL Amyloidosis Pathogenesis is Entirely Related to Immunoglobulin Free Light Chain (FLC) Deposition
- 5 Pathophysiology
- 6 "Stickiness" Dictates Rapidity of Overt Clinical Presentation
- 7 AL Amyloidosis Diagnosis
- 8 Cardiac Biopsy -H&E
- 9 Cardiac Biopsy - Congo Red
- 10 Renal Biopsy -Immunofluorescence
- 11 Renal Biopsy-Electron Microscopy
- 12 Cardiac Involvement is the Single Most Important Prognostic Factor in AL Amyloidosis
- 13 Progressive Improvement in OS in AL Amyloidosis
- 14 Diagnostic and Therapeutic Considerations
- 15 Heme Response Criteria in AL Amyloidosis: the Impact of Deep FLC Suppression
- 16 Therapeutic Approach to Newly Diagnosed AL Amyloidosis Patients
- 17 The Andromeda Study: DaraCyBorD versus CyBorD in Newly Diagnosed AL Amyloidosis
- 18 Andromeda: Patient Characteristics
- 19 Superior Hematologic and Organ Response for DaraCyBorD..
- 20 Cardiac Response Impact OS in AL Amyloidosis
- 21 Graded Cardiac Response Criteria -2022
- 22 Complete Cardiac Response Can Potentially Reverse Dismal Outcome of Stage IIIB Patients
- 23 Lack of cardiac response and less than VGPR increase risk of cardiac progression
- 24 Pan Amyloid Antibody AT-01 to Detect Amyloid Deposition Across the Entire Body
- 25 Florbetapir for Early Cardiac Amyloidosis Diagnosis
- 26 T(11;14) is the Most Common Cytogenetic Abnormality in AL Amyloidosis, an Adverse Prognostic Factor and a Negative Predict Factor of Response to Bortezomib
- 27 T(11;14) is a Predictive Biomarker of Response to Venetoclax in MM
- 28 Venetoclax-based Treatment in AL Amyloidosis Appears Effective in t(11;14)
- 29 BCMA is a Highly Expressed Protein on the Surface of Plasma Cells and an Ideal Target for Immune- and Cellular Therapies
- 30 BCMA Bispecific T-cell Engagers (BITEs)
- 31 Teclisimab - the First BITE Approved for Multiple Myeloma
- 32 BCMA CAR-T Cell in AL Amyloidosis
- 33 CAEL-101, a MoAb Specific to Misfolded FLC, Elicits Cardiac Response in AL Amyloidosis
- 34 Pan Amyloid-Targeting Strategies in the Pipeline
- 35 The rationale behind combining anti-fibrillary MoAbs and Chemotherapy
- 36 Our Pledge at the BWH/DFCI Amyloid Program
